Data On Avicena’s Drug Candidate HD-02 Presented At The 2007 World Congress On Huntington’s Disease

Avicena Group, Inc. (OTCBB: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Drs. Steven Hersch and Diana Rosas presented results regarding the Company’s novel Huntington’s disease treatment candidate HD-02 at the 2007 World Congress on Huntington’s Disease in Dresden, Germany. Drs. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 20th, 2007